Abstract

Purpose

To evaluate the characteristics of corneal parameters in patients with diabetic macular oedema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.

Methods

Participants in this study were 36 patients with DME, treated with either intravitreal ranibizumab (n = 16) or aflibercept (n = 20). All participants underwent best-corrected visual acuity (BCVA) measurement, optical coherence tomography and non-contact specular microscopy to evaluate corneal endothelium parameters (endothelial cell density-ECD, hexagonality, coefficient of variation of the cell size and central corneal thickness-CCT), at baseline and at months 6 and 12 after the first intravitreal injection. Comparisons between baseline and months 6 and 12 were performed.

Results

There was no statistically significant difference regarding ECD, hexagonality, coefficient of variation of the cell size and CCT at month 6 and 12 post initial injection compared to baseline in patients with DME. BCVA improved significantly at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Central retinal thickness was significantly reduced at month 6 and 12 compared to baseline (p < 0.001 for both comparisons).

Conclusion

Intravitreal anti-VEGF injections in patients with DME were found not to affect corneal parameters, namely ECD, hexagonality, coefficient of variation of the cell size and CCT at the long-term follow-up of 12 months.

中文翻译：

---

玻璃体内注射抗血管内皮生长因子对糖尿病性黄斑水肿患者角膜内皮的影响

摘要

目的

评估玻璃体内注射抗血管内皮生长因子 (anti-VEGF) 治疗的糖尿病黄斑水肿 (DME) 患者角膜参数的特征。

方法

本研究的参与者是 36 名 DME 患者，接受玻璃体内雷珠单抗 ( n  = 16) 或阿柏西普 ( n  = 20) 治疗。所有参与者都接受了最佳矫正视力 (BCVA) 测量、光学相干断层扫描和非接触镜面显微镜以评估角膜内皮参数（内皮细胞密度 - ECD、六边形、细胞大小变异系数和中央角膜厚度 - CCT） ，在基线和第一次玻璃体内注射后的第 6 个月和第 12 个月。进行了基线与第 6 个月和第 12 个月之间的比较。

结果

与 DME 患者的基线相比，初次注射后第 6 个月和第 12 个月的 ECD、六边形、细胞大小变异系数和 CCT 没有统计学显着差异。与基线相比，BCVA 在第 6 个月和第 12 个月显着改善（ 两种比较p < 0.001）。与基线相比，中央视网膜厚度在第 6 个月和第 12 个月显着降低（ 两种比较p < 0.001）。

结论

在 12 个月的长期随访中，发现对 DME 患者进行玻璃体内注射抗 VEGF 不会影响角膜参数，即 ECD、六边形、细胞大小变异系数和 CCT。